Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

NCT03248570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Castration Resistant Prostatic Cancer
Metastatic Prostate Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Chemotherapy

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]